The world’s first and only malaria drug for newborns has been cleared globally, marking a crucial step towards addressing a long-standing gap in malaria care. Coartem (artemether-lumefantrine) Baby, developed by Medicines for Malaria Venture (MMV) and Novartis, has been prequalified by the World Health Organization (WHO) as the first and only antimalarial developed specifically for newborns and […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!